<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495651</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12136 TEMPRANO</org_study_id>
    <nct_id>NCT00495651</nct_id>
  </id_info>
  <brief_title>Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)</brief_title>
  <acronym>TEMPRANO</acronym>
  <official_title>Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Temprano trial is based on the following assumptions:&#xD;
&#xD;
        -  ART initiation at CD4 counts &lt;800/mm3 could significantly reduce the probability of&#xD;
           severe HIV-related morbidity or death in the medium term.&#xD;
&#xD;
        -  Tuberculosis and tuberculosis-related deaths are likely to represent a considerable&#xD;
           proportion of morbidity and mortality among HIV-infected patients with high CD4 counts&#xD;
           in sub-Saharan Africa. Therefore, 6-month Isoniazide Prophylaxis for Tuberculosis (IPT)&#xD;
           and early ART could enhance each others efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The main individual benefit of very early ART initiation is likely a reduction in early&#xD;
           severe AIDS-defining and non-AIDS-defining morbidity. While the diseases that might&#xD;
           justify earlier initiation in high-income countries are generally non-infectious&#xD;
           (non-AIDS-defining malignancies, renal diseases and cardiovascular diseases), the&#xD;
           leading cause of early severe AIDS-defining morbidity in sub-Saharan Africa is&#xD;
           tuberculosis and the main causes of severe non-AIDS-defining morbidity are non-invasive&#xD;
           bacterial diseases. As a result of poor access to diagnosis and care, some HIV-infected&#xD;
           people die from early infectious diseases before reaching current WHO criteria for&#xD;
           starting ART.&#xD;
&#xD;
        -  Although the Côte d'Ivoire National Tuberculosis Program (PNLT) does not authorize the&#xD;
           use of prophylaxis against tuberculosis, it has allowed the Temprano trial to provide a&#xD;
           six-month course of isoniazid (INH) prophylaxis to half of the study subjects. This will&#xD;
           allow us to (i) put early ART in perspective with a early 6-month INH prophylaxis use,&#xD;
           in a setting where tuberculosis is the first cause of severe HIV-associated morbidity;&#xD;
           and (ii) to describe and assess the feasibility of a six-month course of INH prophylaxis&#xD;
           among patients with high CD4 counts.&#xD;
&#xD;
        -  Some drug toxicities are immediate but reversible. If early ART is compared to no ART in&#xD;
           the short term, these toxicities may demonstrate erroneously that early ART is&#xD;
           unfavorable. The risks and benefits of early ART initiation should therefore be&#xD;
           evaluated over the long term. In the Temprano trial, we will: (i) follow patients for at&#xD;
           least 30 months and analyze the primary outcome at 30 months; (ii) follow some study&#xD;
           subjects for 80 months and evaluate the evolution of the ART efficacy / toxicity ratio&#xD;
           from month 30 to month 80 as a secondary endpoint, to inform future policies if early&#xD;
           ART is found to be beneficial at 30 months.&#xD;
&#xD;
      Main objective: To assess the benefits and risks of starting ART immediately and/or to&#xD;
      receive a 6-month IPT among HIV-infected adults with CD4 counts &lt;800mm3 and no criteria for&#xD;
      starting ART immediately according to the most recent WHO guidelines.&#xD;
&#xD;
      Location: Abidjan, Côte d'Ivoire.&#xD;
&#xD;
      Methods: randomized 2x2 factorial superiority trial&#xD;
&#xD;
      Main inclusion criteria: (i) HIV-1 or HIV-1+2 infection; (ii) age &gt;18 years; (iii) nadir CD4&#xD;
      count &lt;800/mm3 and no criteria for starting ART immediately according to the most recent WHO&#xD;
      guidelines; and (iv) no active tuberculosis.&#xD;
&#xD;
      Trial arms: Arm I: ART initiation according to WHO criteria, at any time during follow-up;&#xD;
      Arm II: INH prophylaxis (300 mg/day) for six months and ART initiation according to WHO&#xD;
      criteria, at any time during follow-up; Arm III: immediate ART initiation, before reaching&#xD;
      the WHO criteria; Arm IV: INH prophylaxis (300 mg/day) for six months and immediate ART&#xD;
      initiation, before reaching the WHO criteria.&#xD;
&#xD;
      First-line ART regimens&#xD;
&#xD;
        -  Tenofovir / emtricitabine + efavirenz for all HIV-1-infected men and all HIV-1-infected&#xD;
           women who meet the following requirements: on effective contraception and no history of&#xD;
           nevirapine use for the prevention of mother-to-child transmission of HIV (PMTCT).&#xD;
&#xD;
        -  Tenofovir / emtricitabine + lopinavir / ritonavir for all HIV-1+2-infected patients and&#xD;
           all women who do not use effective contraception or who have a history of nevirapine use&#xD;
           for PMTCT.&#xD;
&#xD;
      Primary endpoint: Death (all-cause), AIDS-defining disease, non-AIDS-defining malignancy, or&#xD;
      non-AIDS-defining invasive bacterial disease.&#xD;
&#xD;
      Main secondary endpoint: Grade 3 or 4 clinical event (including renal and cardiovascular&#xD;
      events) or laboratory test result, as defined by the ANRS classification system of&#xD;
      drug-related adverse events.&#xD;
&#xD;
      Final primary analysis: It will be performed once the last patient has reached 30 months of&#xD;
      follow-up. Time-dependent analyses will compare the primary outcome : (i) among patients&#xD;
      initiating ART immediately (arms III and IV) versus patients initiating ART according to the&#xD;
      WHO criteria (arms I and II); (ii) among patients who were prescribed a 6-months (arms II and&#xD;
      IV) IPT versus those who were not (arms I and III).&#xD;
&#xD;
      Intermediate analysis on safety criteria:&#xD;
&#xD;
        -  Toxicity: all-cause mortality. We have not planned to perform any intermediate analyses&#xD;
           for this criterion. If the number of observed deaths is higher than anticipated,&#xD;
           however, the DSMB may decide to carry one out. In this case, we will adjust the alpha&#xD;
           coefficient using the method suggested by Pocock to account for the large variety of&#xD;
           available tests.&#xD;
&#xD;
        -  Efficacy: incidence of severe morbidity. Intermediate analysis: We have not planned any&#xD;
           intermediate analyses for this criterion. If the number of severe morbidity evens is&#xD;
           higher than anticipated once all patients have reached 12 months of follow-up, the DSMB&#xD;
           may decide to carry one out. In this case, we will adjust the alpha coefficient using&#xD;
           the method suggested by Haybittle-Peto, to account for the large variety of available&#xD;
           tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death (all-cause), or severe HIV-related disease (AIDS-defining diseases, non-AIDS-defining malignancies, and non-AIDS-defining invasive bacterial diseases)</measure>
    <time_frame>30 months</time_frame>
    <description>Severe HIV-related disease are defined as AIDS-defining diseases, non-AIDS- defining malignancies, and non-AIDS-defining invasive bacterial diseases&#xD;
Invasive bacterial diseases are defined as: bacteremia, or bacterial infection of any solid organ or aseptic cavity (eg: pneumonia, pleurisy, meningitis,pyomyositis, pyelonephritis, prostatitis, orchitis, epididymitis, salpingitis, endometritis, endocarditis, cholecystitis, visceral abscesses).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>prevalence of HIV resistance (ANRS12253 associated study)</measure>
    <time_frame>30 month after ARV initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 clinical events (including cardiovascular, renal and bone disease) and laboratory test results, as defined by the ANRS classification system of drug-related adverse events</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tuberculosis disease or tuberculosis-related death</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4 counts</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance to antiretroviral medications</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual socio-economic factors</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversions and reversions of repeated QuantiFERON® TB Gold tests between inclusion and month 12 (M12)(ANRS12224 associated study)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of each trial arm in the short- and long-term</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2073</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care+Isoniazid Prophylaxis:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early Antiretroviral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early Antiretroviral therapy + Isoniazid prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral medications</intervention_name>
    <description>Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral medications+Isoniazid prophylaxis</intervention_name>
    <description>Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.&#xD;
Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral medications</intervention_name>
    <description>Early ART initiation on the day of inclusion, before reaching the current WHO criteria</description>
    <arm_group_label>III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral medications+Isoniazid prophylaxis</intervention_name>
    <description>Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria&#xD;
Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion</description>
    <arm_group_label>IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 or HIV-1 + HIV-2 infection&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  No ongoing active tuberculosis&#xD;
&#xD;
          -  Home address in any district of the greater Abidjan area&#xD;
&#xD;
          -  Written informed consent before any clinic visit or laboratory test&#xD;
&#xD;
          -  Clinical and immunologic status:CD4 counts &lt;800/mm3 and no criteria for starting ART&#xD;
             according to the most recent WHO guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  HIV-2 infection alone&#xD;
&#xD;
          -  Clinical signs suggesting a severe disease (including tuberculosis) that has not yet&#xD;
             been diagnosed, such as fever, wasting, diarrhea or unexplained cough (partial list)&#xD;
&#xD;
          -  Previous ART initiation&#xD;
&#xD;
          -  Known severe renal, cardiac or hepatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Anglaret, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Bordeaux 2</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serge Eholié, MD, MSc, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Treichville, Abidjan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de prise en charge de personnes vivant avec le VIH la pierre angulaire</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Prise en Charge et de Formation ACONDA</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Suivi des donneurs de sang, Centre National de Transfusion Sanguine</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Intégré de Recherches Biocliniques d'Abidjan</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre médico-social El Rapha</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Formation Sanitaire Urbaine Anonkoua Kouté</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Général Felix Houphouet Boigny</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales, CHU de Treichville</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de Soins Ambulatoires et de Conseil, CHU de Treichville</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://mereva.net/temprano</url>
    <description>ANRS 12136 Temprano trial website</description>
  </link>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>July 2, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HAART</keyword>
  <keyword>Early Intervention</keyword>
  <keyword>Naive patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

